echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > "2 mg/week", FDA approves larger dose of "semaglutide" for diabetes treatment

    "2 mg/week", FDA approves larger dose of "semaglutide" for diabetes treatment

    • Last Update: 2022-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Compiled and organized by Yimaitong, please do not reprint without authorization
    .

    The U.
    S.
    Food and Drug Administration recently approved a larger-strength (2 mg/week) weekly formulation of the GLP-1 receptor agonist semaglutide (Ozempic, Novo Nordisk) for adults with type 2 diabetes treatment
    .

    The approval was based on the results of the SUSTAIN FORTE study, which included a 40-week randomized controlled study of 961 participants, and the 2 mg/week group decreased HbA1c by a further 0.
    23% compared with the 1 mg/week group, and the former lost more weight.
    Obvious
    .

    Dr.
    Juan Pablo Frias from the National Institutes of Drug strengths provide an additional option
    .

    " Yimaitong compiled and compiled from: Mitchel L.
    Zoler.
    FDA Okays Semaglutide Higher Dose, 2 mg/Week, for Type 2 Diabetes[EB/OL].
    [2022-3-29] .
    https://
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.